Maze Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MAZE and other ETFs, options, and stocks.

About MAZE

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. 

CEO
Jason V. Coloma
CEOJason V. Coloma
Employees
125
Employees125
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2017
Founded2017
Employees
125
Employees125

MAZE Key Statistics

Market cap
1.93B
Market cap1.93B
Price-Earnings ratio
-18.36
Price-Earnings ratio-18.36
Dividend yield
Dividend yield
Average volume
304.39K
Average volume304.39K
High today
$41.78
High today$41.78
Low today
$38.00
Low today$38.00
Open price
$41.30
Open price$41.30
Volume
59.66K
Volume59.66K
52 Week high
$43.29
52 Week high$43.29
52 Week low
$6.71
52 Week low$6.71

Stock Snapshot

As of today, Maze Therapeutics(MAZE) shares are valued at $40.12. The company's market cap stands at 1.93B, with a P/E ratio of -18.36.

During the trading session on 2026-01-14, Maze Therapeutics(MAZE) shares reached a daily high of $41.78 and a low of $38.00. At a current price of $40.12, the stock is +5.6% higher than the low and still -4.0% under the high.

Trading activity shows a volume of 59.66K, compared to an average daily volume of 304.39K.

The stock's 52-week range extends from a low of $6.71 to a high of $43.29.

The stock's 52-week range extends from a low of $6.71 to a high of $43.29.

MAZE News

TipRanks 6d
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale

New insider activity at Maze Therapeutics, Inc. ( (MAZE) ) has taken place on January 8, 2026. Claim 70% Off TipRanks Premium Director Catherine Sohn has offl...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MAZE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .